Colorectal Cancer Clinical Trials in Boston

Showing 41-60 of 134 trials

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more

Elicio Therapeutics25 participantsStarted Oct 2021

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +7 more locations

RECRUITINGPHASE1< 1 mile

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Revolution Medicines, Inc.604 participantsStarted Sep 2023

Sacramento, California, United States • New Haven, Connecticut, United States • Sarasota, Florida, United States +14 more locations

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Colorectal Cancer Trials in Other Cities

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

MGD019 DART® Protein in Unresectable/Metastatic Cancer

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Impact of a Patient-Centered Program for Low Anterior Resection Syndrome a Multicenter Randomized Controlled Trial

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Other Conditions in Boston